Muscle-Invasive Bladder Cancer with ATM, RB1, ERCC2, and FANCC mutations
Yüksel Ürün shared a post on X about a recent paper by Elizabeth Plimack et al. titled “Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial” published in ScienceDirect.
Authors: Elizabeth Plimack, Catherine Tangen, Melissa Plets, Rutika Kokate, Joanne Xiu, Chadi Nabhan, Eric Ross, Erin Grundy, Woonyoung Choi, Colin Dinney, I-Ling C. Lee, Megan Fong, Scott Lucia, Siamak Daneshmand, Dan Theodorescu, Amir Goldkorn, Seth Lerner, Thomas Flaig, David McConkey
“Muscle-Invasive Bladder Cancer with ATM, RB1, ERCC2, and FANCC mutations likely respond to neoadjuvant cisplatin-based chemotherapy, resulting in cancer-free surgical specimens (ypT0) It may help patient selection for bladder preservation post-NAC!”
Source: Yüksel Ürün/X
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes.
